{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:24:57Z","timestamp":1791581097890,"version":"4.3.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors have revolutionized the treatment of urothelial bladder cancer (UBC), yet response remains limited to a subset of patients. The SWItch\/sucrose non-fermentable (SWI\/SNF) chromatin remodeling complex is recurrently altered across cancers, but its prevalence, functional impact, and predictive value in UBC remain unclear. This study aimed to comprehensively delineate the mutational spectrum of SWI\/SNF genes in UBC and assess their utility as predictive biomarkers for response to immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed tumor specimens from 49 patients in the Daping Cohort and integrated data from five independent public cohorts comprising 2,280 cases in total. Somatic alterations were identified using targeted or whole-exome sequencing, and transcriptomic profiles were obtained from RNA sequencing datasets. Survival outcomes were evaluated using Kaplan\u2013Meier survival analysis and time-dependent ROC curves. Tumor immune landscape was characterized via xCell-based deconvolution and corroborated by multiplex immunofluorescence on institutional samples. Prognostic modeling was performed across 65 machine-learning configurations, encompassing survival SVM, CoxBoost, and stepwise Cox, with external validation in independent cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SWI\/SNF alterations were present in 42.8% of UBCs, with the highest frequencies in\n                      <jats:italic>ARID1A, ARID1B, ARID2, SMARCA4<\/jats:italic>\n                      , and\n                      <jats:italic>PBRM1<\/jats:italic>\n                      . Tumors harboring these alterations displayed higher tumor mutational burden, increased neoantigen load, an immune-inflamed microenvironment, and a significantly improved overall survival following immune checkpoint blockade (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). Genotype-specific models achieved strong prognostic discrimination (C-index &amp;gt; 0.75), with AUCs up to 0.909 in SWI\/SNF-mutant and 0.772 in wild-type tumors, substantially outperforming single-modality biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SWI\/SNF alterations define an immunotherapy-responsive stratification of UBC. The accompanying genotype-specific prognostic models provide a ready-to-test framework for guiding precision immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1708324","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:46Z","timestamp":1765175386000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["SWI\/SNF complex alterations predict immunotherapy response in bladder cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangkun","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-ang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg\/kg Plus Ipilimumab 3 mg\/kg Expansion Cohort Results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.009","article-title":"Phase 1 study of chemoradiotherapy combined with nivolumab \u00b1 Ipilimumab for the curative treatment of muscle-invasive bladder cancer","volume":"82","author":"de Ruiter","year":"2022","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34125","article-title":"Survival after neoadjuvant\/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer","volume":"151","author":"Einerhand","year":"2022","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2116863","article-title":"The wild west of checkpoint inhibitor development","volume":"386","author":"Beaver","year":"2022","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"B9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e70348","DOI":"10.1111\/jcmm.70348","article-title":"The role of SWI\/SNF complex in bladder cancer","volume":"29","author":"Lei","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-024-02015-w","article-title":"Assessment of SWI\/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer","volume":"23","author":"Zhuang","year":"2024","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human Malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7150\/jca.91955","article-title":"ARID1B deficiency leads to impaired DNA damage response and activated cGAS-STING pathway in non-small cell lung cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e000438","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41467-020-15959-6","article-title":"PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.04.006","article-title":"ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma","author":"Li","year":"2016","journal-title":"Hum Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e62483","DOI":"10.1371\/journal.pone.0062483","article-title":"ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors","volume":"8","author":"Balb\u00e1s-Mart\u00ednez","year":"2013","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e70398","DOI":"10.1002\/cam4.70398","article-title":"Genetic alterations in chromatin regulatory genes in upper tract urothelial carcinoma and urothelial bladder cancer","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cPrimary\u201d and \u201cSecondary\u201d Muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","article-title":"Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer","volume":"13","author":"Damrauer","year":"2022","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"111859","DOI":"10.1016\/j.celrep.2022.111859","article-title":"Genomic heterogeneity as a barrier to precision oncology in urothelial cancer","volume":"41","author":"Clinton","year":"2022","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","article-title":"Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/thno.100793","article-title":"PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer","volume":"15","author":"Li","year":"2025","journal-title":"Theranostics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4103\/sjg.SJG_184_17","article-title":"Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis","volume":"23","author":"Kim","year":"2017","journal-title":"Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc"},{"key":"B27","doi-asserted-by":"publisher","first-page":"eabc4220","DOI":"10.1126\/scitranslmed.abc4220","article-title":"ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC","volume":"12","author":"Goswami","year":"2020","journal-title":"Sci Trans Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.04.025","article-title":"ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity","volume":"187","author":"Maxwell","year":"2024","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0044","article-title":"Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type","volume":"85","author":"Raupach","year":"2025","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2174\/1568009614666140725094125","article-title":"CRIM1, the antagonist of BMPs, is a potential risk factor of cancer","volume":"14","author":"Zeng","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"B32","doi-asserted-by":"publisher","first-page":"B009","DOI":"10.1158\/2326-6074.CIMM25-B009","article-title":"Abstract B009: Targeting PAR-2 improves tumor antigen presentation and primes the immune system for anti-PD-1 immunotherapy","volume":"13","author":"Aouad","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s12672-025-03051-8","article-title":"Nuclear receptor subfamily 1 group D member 2 induces chemoresistance in ovarian cancer by regulating ferroptosis and immune infiltration","volume":"16","author":"Wang","year":"2025","journal-title":"Discov Onc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.009","article-title":"Atypical chemokine receptors: emerging therapeutic targets in cancer","volume":"43","author":"Torphy","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1182\/blood-2022-165925","article-title":"Pltp regulates BCR signaling and tumor microenvironment in diffuse large B-cell lymphoma through reprogramming of lipid metabolism environment","volume":"140","author":"Shi","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e29312","DOI":"10.1016\/j.heliyon.2024.e29312","article-title":"The causal impact of complement C3d receptor 2 on head and neck cancer microenvironment and its implications for immunotherapy response prediction","volume":"10","author":"Ding","year":"2024","journal-title":"Heliyon"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.036","article-title":"Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy","volume":"148","author":"Groeneveld","year":"2021","journal-title":"Eur J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12672-024-00982-6","article-title":"CXCL10 could be a prognostic and immunological biomarker in bladder cancer","volume":"15","author":"Yin","year":"2024","journal-title":"Discov Onc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e003521","DOI":"10.1136\/jitc-2021-003521","article-title":"Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma","volume":"9","author":"Reschke","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:47Z","timestamp":1765175387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1708324"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1708324","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1708324"}}